The UK enters this moment in personalised medicine and AI with significant underlying strengths: world-class science, leadership in genomics, a unified health system, and a strong research base.
However, the central challenge is not only scientific capability. It is whether the UK can translate these strengths into scaled clinical impact, economic value, and sustained global competitiveness. Our response to the House of Lords Science and Technology Committee’s call for evidence on personalised AI and medicine emphasised a core structural challenge: while the UK continues to generate strong research, it has been less effective at translating this into sustained business R&D investment and industrial scale.
We also highlighted that universities also have a broader role to play in better equipping the UK workforce to respond to the opportunities afforded by AI – including within precision medicine. There are important questions around how universities embed AI into their approaches to teaching, learning outcomes, and research at pace.
Share this consultation response
